The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.
San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.
AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.
J INTS BIO has announced that the Phase 1/2 clinical trial of its new oral 4th generation EGFR TKI, named "JIN-A02," for treating non-small cell lung cancer (NSCLC).
AceLink Therapeutics has reported positive preliminary findings for AL01211, an oral medication being developed to treat Fabry and Type 1 Gaucher diseases.
Kura Oncology has initiated its Phase 1 clinical trial, KOMET-008, which involves administering the menin inhibitor ziftomenib in tandem with gilteritinib.
On February 16, 2024, a significant milestone in cancer treatment was achieved with the FDA's approval of the first-ever single-session cell therapy for solid tumors, marking an innovative step forward in the field.